Table 2

Clinical and laboratory data from complicated and uncomplicated T1D patients; normal human subjects serve as controls.

Subjects

Number of sera

Age (years ± SD)

Gender (M:F)

Smoking duration n(years ± SD)

Duration of disease (years ± SD)

Fasting blood glucose (mg/dl)

HbA1C (%)

Hyperten-sion 140/90 (%)

Carbonyl Content (nmol/mg protein)


Uncomplic-ated T1D

60

30 ± 09

37:23

8(5 ± 3.4)

09 ± 5.6

238 ± 27#

7.9 ± 0.7

36(60)

3.0 ± 0.22#

Complicated T1D Nephropathy

20

37 ± 11

12:8

14(6 ± 3.8)

14 ± 4.9

311 ± 21*

8.8 ± 0.6*

17(85)

3.4 ± 0.28*

Complicated T1D Retinopathy

20

42 ± 14

11:9

17(8 ± 3.6)

17 ± 4.3

335 ± 17*

9.3 ± 0.7*

16(80)

3.9 ± 0.31*

Control

50

32 ± 8

28:22

--

--

96 ± 11.2

5.8 ± 0.4

4(8)

2.1 ± 0.17


Data are means ± SD or n represents number of smokers from given total respective subjects. For blood glucose estimations, blood was collected in oxalated fluoride containers and the assays were performed immediately. Hypertension is defined as sitting systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg or the use of antihypertensive medication. Signs * and # represents p values < 0.001 and < 0.05 respectively.

Khan et al. BMC Immunology 2011 12:19   doi:10.1186/1471-2172-12-19

Open Data